A Randomized, Open-label, Phase 3 Trial of A+AVD Versus ABVD as Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma
A Randomized, Open-label, Phase 3 Trial of A+AVD Versus ABVD as Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma
This open-label, randomized, 2-arm, multicenter, phase 3 study has the primary objective of comparing the modified progression-free survival (mPFS) obtained with brentuximab vedotin (ADCETRIS®) plus AVD (doxorubicin [Adriamycin], vinblastine, and dacarbazine; abbreviated A+AVD) versus that obtained with ABVD (doxorubicin [Adriamycin],bleomycin, vinblastine, and dacarbazine) for the frontline treatment of advanced classical Hodgkin lymphoma(HL)
Inclusion Criteria:
Exclusion Criteria:
Please note that there are additional exclusion criteria. The study center will determine if you meet all of the criteria.
Rionero in Volture, Italy
Torrette Di Ancona, Italy
Chikusa-ku, Nagoya, Japan
Aoba-ku, Sendai-city, Japan
Isehara-shi, Japan
L0dz, Poland
Hwasun-gun, Jeollanam-do, South Korea
Seocho-gu, Seoul, South Korea
Chiayi County 613, Taiwan
Taoyuan County, Taiwan
Norfolk, United Kingdom